PMID- 18247310 OWN - NLM STAT- MEDLINE DCOM- 20090313 LR - 20161124 IS - 1003-9406 (Print) IS - 1003-9406 (Linking) VI - 25 IP - 1 DP - 2008 Feb TI - [Detection of 3q27 chromosomal abnormality in diffuse large B cell lymphoma using FISH on cell microarray]. PG - 73-7 AB - OBJECTIVE: To investigate the association of 3q27 chromosome rearrangement with bcl-6 gene amplification and the molecular classification, therapeutic efficacies, and clinical stages in diffuse large B cell lymphoma (DLBC). METHODS: The newly invented cell microarray was used to detect 3q27 chromosome rearrangement and bcl-6 gene amplification in 60 cases of DLBCL by fluorescence in situ hybridization (FISH). The molecular classification of germinal center B-cell-like (GCB) and non-germinal center B-cell-like (non-GCB) was investigated by analyzing the expression of CD20, CD10, bcl-6 and MUM1 simultaneously by immunohistochemical S-P method and tissue microarray. The information of therapeutic efficacies and clinical stages was obtained by analyzing clinical cases. The relationships among the factors were analyzed by statistics. RESULTS: In 60 cases of DLBCL, 48.3%(29/60) were GCB and 51.7%(31/60) were non-GCB. The 3q27 chromosome rearrangement and bcl-6 gene amplification were present in 15 and 22 cases respectively. In 15 cases with 3q27 rearrangement, bcl-6 protein expression was positive in 3(20.0%), which was significantly different from that in cases without 3q27 rearrangement (P=0.017). In 60 cases of DLBCL, bcl-6 gene amplification was present in 22 cases, in which 5(22.7%) were GCB and 17(77.3%) were non-GCB, which was significantly different from that in cases without bcl-6 gene amplification (P=0.003). In 36 cases undergoing the normal CHOP program treatment, bcl-6 gene amplification was present in 15 cases and the rates of the complete remission, partial remission and no change were 4(26.7%), 4(26.7%) and 7(46.7%) respectively, and again it was significantly different from that in cases without bcl-6 gene amplification (P=0.016). There were no statistical significances among bcl-6 gene, BCL-6 protein expression, and clinical stages. Cases with BCL-6 protein positive and negative expression were not correlated with therapeutic efficacies and clinical stages. CONCLUSION: There is lower expression of BCL-6 protein in cases with bcl-6 gene fragmentation. Cases with bcl-6 gene amplification are non-GCB with worse therapeutic results and later clinical stages. There may be other genes near chromosome 3q27 associated with DLBCL prognosis. FAU - Jiang, Hui-yong AU - Jiang HY AD - Department of Pathology, Affiliated South Hospital, Southern Medical University, Guangzhou, Guangdong, 510515 People's Republic of China. FAU - Li, Hui-ling AU - Li HL FAU - Zhao, Tong AU - Zhao T LA - chi PT - Journal Article PL - China TA - Zhonghua Yi Xue Yi Chuan Xue Za Zhi JT - Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics JID - 9425197 RN - 0 (BCL6 protein, human) RN - 0 (DNA-Binding Proteins) RN - 0 (Proto-Oncogene Proteins c-bcl-6) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - B-Lymphocytes/metabolism MH - *Chromosome Aberrations MH - Chromosomes, Human, Pair 3/*genetics MH - DNA-Binding Proteins/genetics MH - Female MH - Gene Amplification MH - Gene Expression Regulation, Neoplastic MH - Germinal Center/pathology MH - Humans MH - In Situ Hybridization, Fluorescence MH - Lymphoma, Large B-Cell, Diffuse/*genetics/metabolism/*pathology/therapy MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Proto-Oncogene Proteins c-bcl-6 MH - Tissue Array Analysis MH - Treatment Outcome EDAT- 2008/02/06 09:00 MHDA- 2009/03/14 09:00 CRDT- 2008/02/06 09:00 PHST- 2008/02/06 09:00 [pubmed] PHST- 2009/03/14 09:00 [medline] PHST- 2008/02/06 09:00 [entrez] AID - 940625018 [pii] PST - ppublish SO - Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Feb;25(1):73-7.